Compass pathways stock forecast.

The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.On Nov 02, 2023, Compass Pathways ( NASDAQ: CMPS) reported Q3 2023 earnings per share (EPS) of -$0.67, up 55.81% year over year. Total Compass Pathways earnings for the quarter were -$33.39 million. In the same quarter last year, Compass Pathways 's earnings per share (EPS) was -$0.43. If you're new to stock investing, here's how to buy …COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

An in-depth look at the leading psychedelic stocks in the U.S stock market this year. Here’s what you need to know. ... Compass Pathways (NASDAQ:CMPS) $350.9 million Developing one psilocybin ...In August 2023 COMPASS Pathways announced a major private placement that initially eased concerns regarding group’s cash runway. Find out why CMPS stock is a Sell.17 de out. de 2022 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.

What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role …

COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range $5.27 $7.96 52-Week Range $5.01 $11.48 Volume 900,582 shs Average Volume 342,967 shs Market Capitalization $370.16 million P/E Ratio N/A Dividend Yield N/A Price Target $46.83 A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Market Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ... Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...

At close: 04:00PM EST. 6.06 0.00 (0.00%) After hours: 07:09PM EST. Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from ...

Jul 6, 2023 · The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC. Cash position at 30 June 2022 of $207.2 million. Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to ...Compass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …Aug 22, 2023 · COMPASS Pathways-stock; ... Compass Pathways has an average price target of $56.82 with a high of $120.00 and a low of $21.00. ... Some analysts will also offer forecasts for metrics like growth ...

COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.Compass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...Biotechnology firm COMPASS Pathways (CMPS) Wednesday announced a private placement of 16.08M American Depositary Shares and warrants to purchase up to 16.08M ADSs at a price of $7.78...6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: CMPS's weekly volatility (9%) has been stable over the past year.Jul 1, 2023 · While Compass Pathways' (CMPS 0.84%) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months. Compass Pathways to participate in upcoming Evercore investor conference. LONDON, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat …

View a financial market summary for CMPS including stock price quote, trading volume, volatility, options volume, statistics, and other important company ...

Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.06:48 PM ET 11/23/2020. Atai Life Sciences, a company that backs Compass Pathways ( CMPS) and other psychedelic drug developers, said Monday that it had closed a $125 million funding round, the ...For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of …WebFor Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... Jul 6, 2023 · The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC. The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? ( NYSE : COMP ) forecast ROE is N/A , which is considered weak . 13 มี.ค. 2566 ... Analysts at Canaccord Genuity (TSX:CF, LSE:CF) have reiterated their 'Buy' rating and US$60 price target for COMPASS Pathways after the ...

Compass Pathways PLC. 5.94. Delayed Data. As of Nov 29. -0.04 / -0.67%. Today’s Change. 5.01. Today ||| 52-Week Range. 11.48.

May 11, 2023 · In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ...

Still, Compass Pathways stock sank 16% in the stock market today. That's after tumbling 12% on Monday from an eight-month high. Compass also reported financial results for the third quarter.CMPS. COMPASS Pathways plc. 5.83. -0.22. -3.64%. COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to ...CMPS stock has been performing well on August 16, 2023, with positive price forecasts and a consensus among analysts to buy the stock. According to data from CNN Money, the 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 21.00.Get the latest COMPASS Pathways plc (CMPS) stock news and headlines to help you in your trading and investing decisions. ... Performance Outlook. Short Term. 2W - 6W. Mid Term. 6W - 9M. Long Term ...WebWe note that hedge funds don't have a meaningful investment in COMPASS Pathways. Atai Life Sciences N.V. is currently the company's largest shareholder with 19% of shares outstanding. The second ...Dec 26, 2020 · Despite having an IPO just three months ago, Compass Pathways ( CMPS -3.64%) is already up a staggering 224% from its IPO price of $17. If you invested $10,000 in its first-ever public offering ... COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...One reason why now's a decent time to buy psychedelics stocks is that there's an ongoing fire sale across the entire industry, thanks to the bear market. Leaders like COMPASS Pathways ( CMPS 3.22% ...COMPASS Pathways Plc American Depository Shares (CMPS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Web

COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.WebKabir Nath, COMPASS Pathways Chief Executive Officer said, ... sold its remainder position on Friday for $121.6 million, according to disclosure by the local Indian stock exchange.COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary. The consensus 12-month price target for Compass Pathways reflects an upside potential of close to 325%. Even the most pessimistic analyst surveyed by Refinitiv thinks that the stock will double ...Instagram:https://instagram. which is the best dental insuranceregion stockgood mutual funds for retirementstocks 52 week low COMPASS Pathways plc (CMPS) share price prediction for 2023, 2024, 2025, 2026 and 2027. CMPS one year forecast. Compass Pathways Plc stock monthly and weekly forecasts.WebDec 1, 2023 · CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings results on November 2nd, 2023. The reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted earnings per share). litptd ameritrade forex broker Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of COMPASS Pathways The definition of company insiders can be subjective and does vary ...Summary. BiotechValley Insights is initiating coverage of COMPASS Pathways with a "Bearish" rating at a $13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then, the stock ... housing shortages LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new positive data demonstrating the potential of COMP360 psilocybin therapy in depression have …COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...Web